Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06845319 · ClinicalTrials.gov registry record · Phase 2

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients

A Phase 2 study of Triple Negative Breast Cancer, sponsored by Medical University of South Carolina.

Recruiting
Registry status
Phase 2
Development phase
43
Enrollment target
1
Study location

NCT06845319 is a Phase 2 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 43 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06845319, a Phase 2 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
Phase 2
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

This is a multi-institute, single-arm Phase II study to assess the efficacy of a 12-18-week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.

Conditions Studied

Triple Negative Breast Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Paclitaxel

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2025-10-20
Est. Completion 2028-10-20
Phase Phase 2

Sponsor

Medical University of South Carolina

755 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06845319

The ClinicalTrials.gov registry entry for NCT06845319 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT06845319 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT06845319 about?

NCT06845319 is a clinical study titled "Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients". This is a multi-institute, single-arm Phase II study to assess the efficacy of a 12-18-week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to u...

What is the current status of trial NCT06845319?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2025-10-20. Estimated completion is 2028-10-20.

What conditions does trial NCT06845319 study?

This clinical trial studies the following conditions: Triple Negative Breast Cancer.

What interventions are being tested in trial NCT06845319?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT06845319?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06845319 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Triple Negative Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Triple Negative Breast Cancer

All registered trials for this condition

South Carolina

All trials with a study site in South Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.